KPTI
Karyopharm Therapeutics Inc. NASDAQ$9.30
Mkt Cap $79.4M
52w Low $3.65
77.0% of range
52w High $10.99
50d MA $8.08
200d MA $6.65
P/E (TTM)
-0.5x
EV/EBITDA
-2.8x
P/B
—
Debt/Equity
-0.8x
ROE
66.9%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
0.40
50d MA
$8.08
200d MA
$6.65
Avg Volume
1.0M
About
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead co…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -2.26 | -3.60 | -59.3% | 8.94 | +0.4% | -4.0% | +5.1% | +3.5% | +8.2% | +8.2% | — |
| Nov 3, 2025 | AMC | -3.47 | -3.82 | -10.1% | 6.07 | -1.2% | -6.9% | -11.7% | -14.0% | -15.0% | -10.4% | — |
| Aug 11, 2025 | AMC | -3.80 | -4.32 | -13.7% | 3.77 | -0.8% | +6.6% | +18.0% | +23.3% | +57.0% | +48.3% | — |
| May 12, 2025 | AMC | -4.21 | -2.77 | +34.2% | 6.15 | -6.5% | -20.0% | -21.1% | -11.5% | -13.5% | -16.6% | — |
| Feb 19, 2025 | AMC | -3.90 | -3.60 | +7.7% | 9.00 | +1.9% | +1.7% | -0.2% | -0.8% | -5.0% | +9.2% | — |
| Nov 5, 2024 | AMC | -4.05 | -3.90 | +3.7% | 12.69 | +0.5% | +4.8% | +4.3% | +3.6% | +9.0% | +6.1% | — |
| Aug 6, 2024 | AMC | -4.35 | -3.00 | +31.0% | 12.60 | +1.2% | -3.4% | -0.2% | -3.6% | -3.0% | -0.9% | — |
| May 8, 2024 | AMC | -4.95 | -4.80 | +3.0% | 15.30 | +2.0% | +4.9% | +6.9% | +9.8% | +6.9% | +10.8% | — |
| Feb 29, 2024 | AMC | -4.35 | -5.40 | -24.1% | 17.40 | +2.6% | +2.1% | +12.9% | +7.4% | +14.7% | +31.9% | — |
| Nov 2, 2023 | AMC | -4.20 | -4.50 | -7.1% | 11.42 | +1.7% | +16.9% | +15.6% | +5.0% | -1.5% | -8.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.66 | $8.99 | +3.8% | +0.0% | -0.7% | -3.0% | -4.0% | +1.3% |
| Mar 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.48 | $5.40 | -1.5% | -3.3% | +1.6% | +6.2% | +7.5% | +15.3% |
| Mar 25 | Baird | Maintains | Outperform → Outperform | — | $5.44 | $5.36 | -1.5% | -4.2% | +2.4% | +0.7% | -2.6% | +2.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.36 | -1.5% | -4.2% | +2.4% | +0.7% | -2.6% | +2.4% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.40 | $9.64 | +2.6% | -1.6% | +2.9% | +2.9% | +6.7% | +7.1% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $6.07 | $6.00 | -1.2% | -6.9% | -11.7% | -14.0% | -15.0% | -10.4% |
| Oct 13 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $5.50 | $6.01 | +9.3% | +2.2% | +4.9% | +8.2% | +9.6% | +7.8% |
| Oct 9 | Baird | Maintains | Outperform → Outperform | — | $5.90 | $5.61 | -4.9% | -1.4% | -6.8% | -4.7% | -2.2% | +0.8% |
| Oct 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.90 | $5.61 | -4.9% | -1.4% | -6.8% | -4.7% | -2.2% | +0.8% |
| Aug 12 | Baird | Maintains | Outperform → Outperform | — | $3.77 | $3.74 | -0.8% | +6.6% | +18.0% | +23.3% | +57.0% | +48.3% |
Recent Filings
8-K
Unknown — 8-K Filing
Karyopharm's runway extending to Q3 2026 suggests manageable near-term solvency, but investors should monitor burn rate closely as the company relies on product revenue growth to avoid future dilutive financing.
Mar 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
KPTI's equity issuance agreement with RA Capital likely dilutes existing shareholders but provides needed capital for operations or clinical development, a mixed signal for near-term stock performance.
Mar 24
8-K · 5.02
!!! Very High
Zevra Therapeutics, Inc. -- 8-K 5.02: Executive Change
Zevra Therapeutics appointed Justin Renz as Chief Financial Officer while he resigned from the board, effective March 9, 2026, signaling potential leadership restructuring.
Mar 9
8-K · 8.01
!! High
Karyopharm Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Karyopharm Therapeutics secured a forbearance agreement delaying debt obligations until late 2026, contingent on completing a capital raise to improve liquidity and avoid default.
Mar 3
8-K
Karyopharm Therapeutics Inc. -- 8-K Filing
I cannot provide a meaningful investor analysis from this filing, as the summary contains only technical XBRL metadata and reference information rather than substantive business details or corporate actions.
Feb 19
8-K
Karyopharm Therapeutics Inc. -- 8-K Filing
Karyopharm Therapeutics reported $115 million in 2025 XPOVIO revenue and guided 2026 total revenue to $130-$150 million, indicating modest growth expectations for its lead oncology drug.
Feb 12
Data updated apr 25, 2026 5:55pm
· Source: massive.com